| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
utilizing plastic film to make absorbent
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Cyanuric acid is rapidly excreted unchanged in rats after administration. Metabolism/Metabolites (14)C-labeled cyanuric acid…after an absorption period of 4 days to 2 weeks, 13.2% and 7.9% of the absorbed radioactivity (in the form of (14)CO2) are released from corn and alfalfa, respectively, followed by a consumption period of up to 6 weeks. Its mechanism of action is triazine ring cleavage. Approximately 90% of the administered dose is reported to be excreted in the urine within 12 hours, of which 99% is identified as cyanuric acid. Biological Half-Life 90% is excreted within 12 hours, of which 99% is excreted unchanged as cyanuric acid; [HSDB] |
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) > 612 mg/m3 Interactions The major pet food recall associated with acute renal failure in dogs and cats initially identified melamine as a suspected toxic substance. During the investigation, cyanuric acid was also found in the problematic food, in addition to melamine. This study aimed to evaluate the toxicity of melamine, cyanuric acid, and the combination of melamine and cyanuric acid to cats. In this preliminary study, 0.5% and 1% melamine were added to the diets of two cats, respectively. Over 10 days, cyanuric acid was added to the diets of one cat at escalating concentrations of 0.2%, 0.5%, and 1%. Additionally, one cat in each dosage group was simultaneously fed melamine and cyanuric acid at concentrations of 0%, 0.2%, 0.5%, and 1%. No renal impairment was observed in cats fed melamine or cyanuric acid alone. Cats that were simultaneously administered both drugs were euthanized 48 hours after administration due to acute renal failure. All cats that received both drugs showed the presence of fan-shaped birefringent lenses in their urine and kidney impressions. Histopathological examination was limited to the kidneys, including lenses primarily located in the distal renal tubules, severe interstitial edema, and hemorrhage at the corticomedullary junction. Estimated concentrations of melamine in the kidneys ranged from 496 to 734 mg/kg wet weight, and estimated concentrations of cyanuric acid ranged from 487 to 690 mg/kg wet weight. These results indicate that the combination of melamine and cyanuric acid was the cause of acute renal failure in the cats. Non-human toxicity values Rat LD50, Sprague-Dawley (male and female) oral >5000 mg/kg body weight Rabbit LD50, New Zealand White Rabbit (male and female) dermal contact >5000 mg/kg body weight Rat LD50 oral 7700 mg/kg body weight Cat LD50 intravenous 2144 mg/kg body weight. /Sodium isocyanurate/ For more complete non-human toxicity data on cyanuric acid (9 types in total), please visit the HSDB record page. |
| Additional Infomation |
Crystals. (NTP, 1992)
Cyanuric acid is an enol tautomer of isocyanuric acid. It is an exogenous substance. It belongs to the 1,3,5-triazine class and heteroaryl hydroxyl class of compounds. It is a tautomer of isocyanuric acid. Cyanuric acid has been reported in Acokanthera oblongifolia, and relevant data are available. |
| Molecular Formula |
C3H3N3O3
|
|---|---|
| Molecular Weight |
129.07
|
| Exact Mass |
129.017
|
| CAS # |
108-80-5
|
| Related CAS # |
Cyanuric acid-13C3;201996-37-4;Cyanuric acid-13C3,15N3
|
| PubChem CID |
7956
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
793.4±43.0 °C at 760 mmHg
|
| Melting Point |
360 °C
|
| Flash Point |
433.6±28.2 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
-1.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZFSLODLOARCGLH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3N3O3/c7-1-4-2(8)6-3(9)5-1/h(H3,4,5,6,7,8,9)
|
| Chemical Name |
1,3,5-triazinane-2,4,6-trione
|
| Synonyms |
Cyanuric acid Isocyanuric acid Isocyanurate acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7477 mL | 38.7387 mL | 77.4773 mL | |
| 5 mM | 1.5495 mL | 7.7477 mL | 15.4955 mL | |
| 10 mM | 0.7748 mL | 3.8739 mL | 7.7477 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
